Stefan Miller is a scientific consultant at Lysando AG and an independent consultant. He has significant experience as a chief scientific officer (CSO) and chief executive officer (CEO) in biotech companies and focuses on technology and product development including intellectual property strategy.

Stefan co-founded Profos AG in 2000 and was its CSO until 2008. There he led the development of microbial diagnostics products and worked on bacteriophage endolysins as novel targeted antibacterials for Gram-positive bacteria.

To overcome the limitations of endolysins, he 2009 started developing Artilysin®s when he co-founded Lysando AG. Stefan worked there as CSO and led the research and development unit at Lisando GmbH as CEO, until 2014 when he became a member of the advisory board of Lysando AG.

Stefan is the author of more than 20 scientific publications and patents.

He received his diploma in biology, and his PhD, from the University of Regensburg, Germany. He did his post-doctorate at the Max-Planck-Institute for Biology in Tübingen, Germany.